ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005

Foundation offers funds for mesothelioma research.

July 9, 2004

Prevention, Centers To Gain, some $$ In President’s Budget

February 8, 1991

DCT Board Okays 11 Concept Contract Recompetitions

October 26, 1984

Group Chairmen Propose Adding Four Trials For High Priority Status

July 6, 1990

Swedish Education Says Nursing Education Should Emphasize Decision Making

December 4, 1987